Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EP Technologies

This article was originally published in The Gray Sheet

Executive Summary

Going public via an initial public offering of 2.5 mil. shares priced between $10 and $12 per share. The company will use the expected net proceeds of $25 mil. to expand its sales and marketing efforts, for research and development activities and for capital equipment, working capital and other corporate purposes. Shares outstanding after the offering will number approximately 9.2 mil. Alex. Brown & Sons and Hambrecht & Quist are underwriting. The firm notes in its registration statement with the Securities and Exchange Commission that a trial date of March 29 has been set to resolve its suit against CardioRhythm, a direct competitor owned by Medtronic. Filed in February 1992 against CardioRhythm and two former EP consultants, the suit alleges misappropriation of trade secrets, unfair competition, breach of implied and written contract and other causes of action. An August 1992 countersuit was filed.
UsernamePublicRestriction

Register

MT000359

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel